{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-188935","form_type":"8-K","ticker":"AMRN","cik":"0000897448","company_name":"AMARIN CORP PLCUK","filed_at":"2026-04-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.907404+00:00","generated_at":"2026-05-15T02:37:20.086797+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Amarin Q1 total revenue up 7% to $45.1M; operating loss narrows 32%; cash flow positive","bullets":["Total net revenue $45.1M (+7% YoY); U.S. product revenue $35.6M flat; European revenue $4.9M (-9%); ROW $2.8M.","Operating loss narrowed to $11.3M from $16.8M; net loss $10.5M ($0.03 EPS) vs $15.7M ($0.04 EPS).","Cash and investments $307.8M; debt-free; second consecutive quarter of positive cash flow.","Reaffirms full-year 2026 positive cash flow; targeting ~$70M cost savings; restructuring charges $39.6M cumulative.","Recordati launched VAZKEPA in 10 European countries; U.S. VAZCEPA branded Rx up 17% YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-188935","json":"https://secwatch.observer/filing/0001193125-26-188935.json","markdown":"https://secwatch.observer/filing/0001193125-26-188935.md","text":"https://secwatch.observer/filing/0001193125-26-188935.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/897448/000119312526188935/0001193125-26-188935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/897448/000119312526188935/amrn-20260429.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T02:37:20.086797+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c8684b8bd04b92f8f2db46daaba9098dd9570a20","claim":"AMARIN CORP PLCUK reported the three months ended March 31, 2026 results: revenue $45.1 million, net income $(10.5) million. Guidance reaffirmed.","evidence_excerpt":"On April 29, 2026, Amarin Corporation plc (“ Amarin ”) issued a press release announcing its financial results for the three months ended March 31, 2026","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/897448/000119312526188935/0001193125-26-188935-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2026"},{"label":"Revenue","value":"$45.1 million"},{"label":"Net income","value":"$(10.5) million"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}